BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

959 related articles for article (PubMed ID: 26724422)

  • 21. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
    Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of neoadjuvant chemotherapy for the patients with locally invasive bladder cancer].
    Noguchi S; Takase K; Yoshida M; Yumura Y; Yamashita Y; Oogo Y; Miyoshi Y
    Nihon Hinyokika Gakkai Zasshi; 2005 Jul; 96(5):548-53. PubMed ID: 16083032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
    J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
    Lehmann J; Retz M; Hack M; Siemer S; Stöckle M
    Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.
    Kaimakliotis HZ; Monn MF; Cho JS; Pedrosa JA; Hahn NM; Albany C; Gellhaus PT; Cary KC; Masterson TA; Foster RS; Bihrle R; Cheng L; Koch MO
    Future Oncol; 2016 Aug; 12(15):1795-804. PubMed ID: 27255805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
    Kaneko G; Kikuchi E; Matsumoto K; Obata J; Nakamura S; Miyajima A; Oya M
    Jpn J Clin Oncol; 2011 Jul; 41(7):908-14. PubMed ID: 21665907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.
    Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A
    Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.
    Millikan R; Dinney C; Swanson D; Sweeney P; Ro JY; Smith TL; Williams D; Logothetis C
    J Clin Oncol; 2001 Oct; 19(20):4005-13. PubMed ID: 11600601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
    Margulis V; Puligandla M; Trabulsi EJ; Plimack ER; Kessler ER; Matin SF; Godoy G; Alva A; Hahn NM; Carducci MA; Hoffman-Censits J;
    J Urol; 2020 Apr; 203(4):690-698. PubMed ID: 31702432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer.
    Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H
    Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.